Disease · MONDO_0005090

schizophrenia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. schizophrenia. Diseases, record MONDO_0005090. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005090

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: schizophrenia; Open Targets
Open Targets ID: MONDO_0005090; Open Targets
Other names: Dementia Praecox, Disorder, Schizophrenic, Disorders, Schizophrenic, Other specified types of schizophrenia, Other specified types of schizophrenia, chronic state, Other specified types of schizophrenia, chronic state with acute exacerbation, Other specified types of schizophrenia, in remission, Other specified types of schizophrenia, subchronic state, Other specified types of schizophrenia, subchronic state with acute exacerbation, Other specified types of schizophrenia, unspecified state, SCHIZO NEC-CHR/EXACERB, SCHIZO NEC-SUBCHR/EXACER, SCHIZO NOS-CHR/EXACERB, SCHIZO NOS-SUBCHR/EXACER, SCHIZOPHRENIA NEC-CHR, SCHIZOPHRENIA NEC-REMISS, SCHIZOPHRENIA NEC-SUBCHR, SCHIZOPHRENIA NEC-UNSPEC, SCHIZOPHRENIA NOS-UNSPEC, SCHIZOPHRENIC DIS, SCZ, Schizophrenia (disorder), Schizophrenia NOS, Schizophrenia NOS (disorder), Schizophrenias, Schizophrenic Disorder, Schizophrenic Disorders, Schizophrenic disorders (disorder), Unspecified schizophrenia, Unspecified schizophrenia (disorder), Unspecified schizophrenia, chronic state with acute exacerbation, Unspecified schizophrenia, subchronic state with acute exacerbation, Unspecified schizophrenia, unspecified state, [X]Schizophrenia, unspecified, [X]Schizophrenia, unspecified (disorder), schizophrenia (disease), schizophrenia-1; Open Targets
Disease Ontology: DOID:5419; Disease Ontology
NCI Thesaurus: C3362; NCI Thesaurus
Orphanet: ORPHA:3140; Orphanet
Highest stage of its drugs: Approval, for 58 of its 345 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs345

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RISPERIDONE	CHEMBL85	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	349	219	219	Drugs and targets
OLANZAPINE	CHEMBL715	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	255	148	146	Drugs and targets
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Approval	DailyMed, EMA Human Drugs, FDA, PMDA and TTD	178	139	139	Drugs and targets
PALIPERIDONE	CHEMBL1621	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	88	78	78	Drugs and targets
QUETIAPINE	CHEMBL716	Small molecule	Approval	TTD	69	68	68	Drugs and targets
PALIPERIDONE PALMITATE	CHEMBL2107360	Small molecule	Approval	DailyMed and PMDA	56	53	53	Drugs and targets
CLOZAPINE	CHEMBL42	Small molecule	Approval	DailyMed, PMDA and TTD	62	50	50	Drugs and targets
ZIPRASIDONE	CHEMBL708	Small molecule	Approval	TTD	42	41	41	Drugs and targets
HALOPERIDOL	CHEMBL54	Small molecule	Approval	DailyMed and TTD	40	33	33	Drugs and targets
LURASIDONE	CHEMBL1237021	Small molecule	Approval	EMA Human Drugs	32	31	31	Drugs and targets

1 to 10 of 345

See all 345 drugs

Targets269

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	61	D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor inhibitor; Dopamine D2 receptor modulator; Dopamine D2 receptor partial agonist; Dopamine receptor agonist; Dopamine receptor antagonist; Dopamine receptors; D2 & D3 antagonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	43	Serotonin (5-HT) receptor antagonist; Serotonin 2 (5-HT2) receptor antagonist; Serotonin 2 receptors; 5-HT2a & 5-HT2c antagonist; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor inverse agonist	Approval	https://conductscience.org/library/genes/3356	Drugs and targets
DRD3	D(3) dopamine receptor	23	D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D3 receptor agonist; Dopamine D3 receptor antagonist; Dopamine D3 receptor modulator; Dopamine receptor agonist; Dopamine receptor antagonist; Dopamine receptors; D2 & D3 antagonist	Approval	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D(4) dopamine receptor	17	D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D4 receptor antagonist; Dopamine receptor agonist; Dopamine receptor antagonist	Approval	https://conductscience.org/library/genes/1815	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	17	Serotonin (5-HT) receptor antagonist; Serotonin 2 (5-HT2) receptor antagonist; Serotonin 2 receptors; 5-HT2a & 5-HT2c antagonist; Serotonin 2c (5-HT2c) receptor agonist; Serotonin 2c (5-HT2c) receptor antagonist	Approval	https://conductscience.org/library/genes/3358	Drugs and targets
CHRNA7	Neuronal acetylcholine receptor subunit alpha-7	10	Neuronal acetylcholine receptor protein alpha-7 subunit agonist; Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist; Neuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/1139	Drugs and targets
SLC6A2	Sodium-dependent noradrenaline transporter	10	Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent	Phase 3	https://conductscience.org/library/genes/6530	Drugs and targets
HTR1A	5-hydroxytryptamine receptor 1A	9	Serotonin (5-HT) receptor antagonist; Serotonin 1a (5-HT1a) receptor agonist; Serotonin 1a (5-HT1a) receptor partial agonist	Approval	https://conductscience.org/library/genes/3350	Drugs and targets
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
SLC6A3	Sodium-dependent dopamine transporter	8	Dopamine transporter inhibitor; Dopamine transporter releasing agent; Sodium-dependent dopamine transporter releasing agent	Phase 3	https://conductscience.org/library/genes/6531	Drugs and targets

1 to 10 of 269

See all 269 targets

Trials1,137

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 21 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02775864	Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia		81,921	2019-06-07	Schizophrenia, Schizoaffective Disorder	BENZODIAZEPINE	Its record names the disease	ClinicalTrials.gov
NCT00856583	Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use	Phase 3	9,809	2011-08-01	Schizophrenia	RISPERIDONE, SERTINDOLE	Its record names the disease	ClinicalTrials.gov
NCT01053429	A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule		3,391	2011-01-07	Bipolar Disorder, Schizophrenia	ZIPRASIDONE	Its record names the disease	ClinicalTrials.gov
NCT01515423	Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia	Phase 3	1,429	2016-05-02	Schizophrenia	PALIPERIDONE PALMITATE	Its record names the disease	ClinicalTrials.gov
NCT00589914	Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia	Phase 3	1,221	2011-10-04	Schizophrenia	PALIPERIDONE PALMITATE, RISPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT01662648	Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia	Phase 3	1,117	2014-03-26	Schizophrenia	PALIPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT00731549	Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia	Phase 3	1,081	2014-11-11	Schizophrenia	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01397786	Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia	Phase 3	1,044	2017-03-27	Schizophrenia	BREXPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03121586	Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia	Phase 3	995	2025-08-24	Schizophrenia	PIMAVANSERIN	Its record names the disease	ClinicalTrials.gov
NCT00706654	Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia	Phase 3	937	2013-08-14	Schizophrenia	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,137

See all 1,137 trials

Comparisons in its trials317

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sertindole vs Risperidone: Number of Participants With Suicide Attempts (Fatal and Non-fatal) - MedDRA	43 of 4,905	65 of 4,904	9,809	NCT00856583	Trial comparisons
Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Cardiac Deaths - MedDRA	17 of 4,905	8 of 4,904	9,809	NCT00856583	Trial comparisons
Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Cardiac Deaths - ISC	31 of 4,905	12 of 4,904	9,809	NCT00856583	Trial comparisons
Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Completed Suicides - MedDRA	13 of 4,905	21 of 4,904	9,809	NCT00856583	Trial comparisons
Sertindole vs Risperidone: Number of Participants With Suicide Attempts (Fatal and Non-fatal) - ISC	68 of 4,905	76 of 4,904	9,809	NCT00856583	Trial comparisons
Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - MedDRA	34 of 4,905	32 of 4,904	9,809	NCT00856583	Trial comparisons
Sertindole vs Risperidone: Number of Participants With Discontinuation of Treatment for Any Reason Other Than Study Closure	3,136 of 4,905	2,597 of 4,904	9,809	NCT00856583	Trial comparisons
Sertindole vs Risperidone: Number of Participants With Hospitalisations, Excluding Hospitalisations Related to the Primary Psychiatric Disease	174 of 4,905	149 of 4,904	9,809	NCT00856583	Trial comparisons
Sertindole vs Risperidone: Second Primary Outcome: Number of Participants With Cardiac Events, Including Arrhythmias, Requiring Hospitalisation	10 of 4,905	6 of 4,904	9,809	NCT00856583	Trial comparisons
Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - ISC	19 of 4,905	28 of 4,904	9,809	NCT00856583	Trial comparisons

1 to 10 of 317

See all 317 comparisons in its trials

Papers from its trials706

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38851166	RESULT	1	PubMed
37528429	RESULT	1	PubMed
37175697	RESULT	1	PubMed
35992380	RESULT	1	PubMed
35211743	RESULT	1	PubMed
34847501	RESULT	1	PubMed
34365585	RESULT	1	PubMed
33239746	RESULT	1	PubMed
32160422	RESULT	1	PubMed
30845818	RESULT	1	PubMed

1 to 10 of 706

See all 706 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005090

GET https://conductscience.org/api/diseases/v1/MONDO_0005090/drugs?page=2

API reference For AI assistants